Abstract
Cardiovascular diseases are common and occur mainly in the elderly in whom osteoporotic fractures also are very common. Because of this, it is of importance to establish whether drugs used in the treatment of cardiovascular diseases affect bone, in order to minimise any possible adverse effects. In the majority of studies, treatment with thiazide diuretics, statins, digoxin, angiotensin-converting enzyme (ACE)-inhibitors, and organic nitrates have not been associated with harmful effects on bone. On the contrary, treatment with these drugs may improve bone strength but because there is a lack of randomised controlled trials (RCTs) with fracture as a primary outcome measure, these drugs should not be prescribed for fracture prevention. In RCTs, treatment with loop diuretics have been shown to increase plasma levels of parathyroid hormone and decrease bone mineral density. In epidemiological studies, treatment with loop diuretics as well as treatment with amiodarone has been associated with an increased risk of fracture. In view of the conflicting results from published studies, no conclusions can be drawn on potential bone effects of treatment with oral anticoagulants, β-blockers, and calcium channel blockers.
Keywords: Bone, fracture, diuretics, amiodarone, statins, antiarrhythmics
Current Drug Safety
Title: Cardiovascular Drugs and Bone
Volume: 3 Issue: 3
Author(s): Lars Rejnmark
Affiliation:
Keywords: Bone, fracture, diuretics, amiodarone, statins, antiarrhythmics
Abstract: Cardiovascular diseases are common and occur mainly in the elderly in whom osteoporotic fractures also are very common. Because of this, it is of importance to establish whether drugs used in the treatment of cardiovascular diseases affect bone, in order to minimise any possible adverse effects. In the majority of studies, treatment with thiazide diuretics, statins, digoxin, angiotensin-converting enzyme (ACE)-inhibitors, and organic nitrates have not been associated with harmful effects on bone. On the contrary, treatment with these drugs may improve bone strength but because there is a lack of randomised controlled trials (RCTs) with fracture as a primary outcome measure, these drugs should not be prescribed for fracture prevention. In RCTs, treatment with loop diuretics have been shown to increase plasma levels of parathyroid hormone and decrease bone mineral density. In epidemiological studies, treatment with loop diuretics as well as treatment with amiodarone has been associated with an increased risk of fracture. In view of the conflicting results from published studies, no conclusions can be drawn on potential bone effects of treatment with oral anticoagulants, β-blockers, and calcium channel blockers.
Export Options
About this article
Cite this article as:
Rejnmark Lars, Cardiovascular Drugs and Bone, Current Drug Safety 2008; 3 (3) . https://dx.doi.org/10.2174/157488608785699469
DOI https://dx.doi.org/10.2174/157488608785699469 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
New Anti-Thrombotic Drugs for Stroke Prevention
Current Vascular Pharmacology Patent Selections
Recent Patents on Biotechnology Cerebrovascular Complications After Heart Transplantation
Current Cardiology Reviews Phytocannabinoids: General Aspects and Pharmacological Potential in Neurodegenerative Diseases
Current Neuropharmacology Long-term Potentiation at Spinal C-fiber Synapses: A Target for Pathological Pain
Current Pharmaceutical Design Environmental Enrichment Influences BDNF and NR1 Levels in the Hippocampus and Restores Cognitive Impairment in Chronic Cerebral Hypoperfused Rats
Current Neurovascular Research Castration Resistant Prostate Cancer: From Emerging Molecular Pathways to Targeted Therapeutic Approaches
Clinical Cancer Drugs Recommendations for the Treatment of Hypertension in Elderly People
Cardiovascular & Hematological Agents in Medicinal Chemistry Association Constants of Pyridine and Piperidine Alkaloids to Amyloid ß Peptide Determined by Electrochemical Impedance Spectroscopy
Current Alzheimer Research Organelle Stress Sensors and Cell Death Mechanisms in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Mind-Body Therapies and Osteoarthritis of the Knee
Current Rheumatology Reviews Alzheimers Disease, Ceramide, Visfatin and NAD
CNS & Neurological Disorders - Drug Targets Editorial (Thematic Issue: Cell Metabolism and Current Challenges in Drug Research)
Current Pharmaceutical Design Analysis of Univariate and Multivariate Filters Towards the Early Detection of Dementia
Recent Advances in Computer Science and Communications Differential Diagnosis of Behavioral Variant and Semantic Variant of Frontotemporal Dementia Using Visual Rating Scales
Current Medical Imaging Transgenic Mouse Models of Tauopathy in Drug Discovery
CNS & Neurological Disorders - Drug Targets Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems
Current Medicinal Chemistry Snapshots of Protein Folding Problem: Implications of Folding and Misfolding Studies
Protein & Peptide Letters The Molecular Mechanism of <i>Scutellaria baicalensis</i> Georgi Stems and Leaves Flavonoids in Promoting Neurogenesis and Improving Memory Impairment by the PI3K-AKT-CREB Signaling Pathway in Rats
Combinatorial Chemistry & High Throughput Screening Inflammation and Innate Immune Response Against Viral Infections in Marine Fish
Current Pharmaceutical Design